Hypothyroidism in patients with multiple myeloma (MM) receiving thalidomide.

被引：0
|
作者：
Badros, A
Zangari, M
Bodenner, D
Siegel, E
Spoon, D
Toor, A
Desikan, R
Arnold, E
Anaissie, E
Zeldis, J
Tricot, G
Barlogie, B
机构：
[1] Univ Arkansas Med Sci, Myeloma & Transplantat Res Ctr, Little Rock, AR 72205 USA
[2] Univ Arkansas Med Sci, Dept Endocrinol, Little Rock, AR 72205 USA
[3] Celgene Corp, Warren, NJ USA
来源：
BLOOD | 2000年 / 96卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
4973
引用
收藏
页码：285B / 285B
页数：1
相关论文
共 50 条
  • [31] Melphalan, thalidomide and decadron (MTD) for refractory/relapsed multiple myeloma (MM).
    Srkalovic, G
    Karam, MA
    McLain, DA
    Hussein, MA
    BLOOD, 1999, 94 (10) : 314B - 315B
  • [32] Angiogenesis factors and sensitivity to thalidomide in previously untreated multiple myeloma (MM).
    Weber, DM
    Rankin, K
    Gavino, M
    Delasalle, K
    Aguayo, A
    Albitar, M
    Alexanian, R
    BLOOD, 2000, 96 (11) : 168A - 168A
  • [33] Thalidomide is effective in the treatment of recurrent. Refractory multiple myeloma (MM).
    Sabir, T
    Raza, S
    Anderson, L
    Jagannath, S
    BLOOD, 1999, 94 (10) : 125A - 125A
  • [34] Serum MUC-1 as a marker of disease status in multiple myeloma patients receiving thalidomide
    Mileshkin, L
    Prince, HM
    Seymour, JF
    Biagi, JJ
    BRITISH JOURNAL OF HAEMATOLOGY, 2003, 123 (04) : 747 - 748
  • [35] Increased risk of deep-vein thrombosis in patients with multiple myeloma receiving thalidomide and chemotherapy
    Zangari, M
    Anaissie, E
    Barlogie, B
    Badros, A
    Desikan, R
    Gopal, AV
    Morris, C
    Toor, A
    Siegel, E
    Fink, L
    Tricot, G
    BLOOD, 2001, 98 (05) : 1614 - 1615
  • [36] Incidence and clinical course of peripheral neuropathy in patients receiving thalidomide for the treatment of multiple myeloma.
    Naina, HVK
    Lacy, MQ
    Dispenzieri, A
    Kumar, S
    Greipp, PR
    Witzig, TE
    Gertz, MA
    Rajkumar, SV
    BLOOD, 2005, 106 (11) : 970A - 970A
  • [37] Survival outcomes of patients receiving thalidomide-dexamethasone for previously untreated multiple myeloma.
    Thomas, Sheeba K.
    Giralt, Sergio A.
    Wang, Michael
    Delasalle, Kay B.
    Gavino, Maria
    Rankin, Kim
    Alexanian, Raymond
    Weber, Donna M.
    BLOOD, 2006, 108 (11) : 1019A - 1019A
  • [38] Immunoreactivity of thalidomide in patients with multiple myeloma.
    Luo, SK
    Li, J
    Hong, WD
    Zhou, ZH
    BLOOD, 2002, 100 (11) : 367B - 367B
  • [39] Thalidomide in patients with multiple myeloma and renal failure
    Fakhouri, F
    Guerraoui, H
    Presne, C
    Peltier, J
    Delarue, R
    Muret, P
    Knebelmann, B
    BRITISH JOURNAL OF HAEMATOLOGY, 2004, 125 (01) : 96 - 97
  • [40] Thalidomide metabolites in mice and patients with multiple myeloma
    Lu, J
    Palmer, BD
    Kestell, P
    Browett, P
    Baguley, BC
    Muller, G
    Ching, LM
    CLINICAL CANCER RESEARCH, 2003, 9 (05) : 1680 - 1688
12345